Browsing by Author "Murphy, Sean V."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- In Situ Bioprinting of Autologous Skin Cells Accelerates Wound Healing of Extensive Excisional Full-Thickness WoundsAlbanna, Mohammed; Binder, Kyle W.; Murphy, Sean V.; Kim, Jaehyun; Qasem, Shadi A.; Zhao, Weixin; Tan, Josh; El-Amin, Idris B.; Dice, Dennis D.; Marco, Julie; Green, Jason; Xu, Tao; Skardal, Aleksander; Holmes, James H.; Jackson, John D.; Atala, Anthony; Yoo, James J. (Springer Nature, 2019-02-21)The early treatment and rapid closure of acute or chronic wounds is essential for normal healing and prevention of hypertrophic scarring. The use of split thickness autografts is often limited by the availability of a suitable area of healthy donor skin to harvest. Cellular and non-cellular biological skin-equivalents are commonly used as an alternative treatment option for these patients, however these treatments usually involve multiple surgical procedures and associated with high costs of production and repeated wound treatment. Here we describe a novel design and a proof-of-concept validation of a mobile skin bioprinting system that provides rapid on-site management of extensive wounds. Integrated imaging technology facilitated the precise delivery of either autologous or allogeneic dermal fibroblasts and epidermal keratinocytes directly into an injured area, replicating the layered skin structure. Excisional wounds bioprinted with layered autologous dermal fibroblasts and epidermal keratinocytes in a hydrogel carrier showed rapid wound closure, reduced contraction and accelerated re-epithelialization. These regenerated tissues had a dermal structure and composition similar to healthy skin, with extensive collagen deposition arranged in large, organized fibers, extensive mature vascular formation and proliferating keratinocytes.
- Multi-tissue interactions in an integrated three-tissue organ-on-a-chip platformSkardal, Aleksander; Murphy, Sean V.; Devarasetty, Mahesh; Mead, Ivy; Kang, Hyun-Wook; Seol, Young-Joon; Zhang, Yu Shrike; Shin, Su-Ryon; Zhao, Liang; Aleman, Julio; Hall, Adam R.; Shupe, Thomas D.; Kleensang, Andre; Dokmeci, Mehmet R.; Lee, Sang Jin; Jackson, John D.; Yoo, James J.; Hartung, Thomas; Khademhosseini, Ali; Soker, Shay; Bishop, Colin E.; Atala, Anthony (Springer Nature, 2017-08-18)Many drugs have progressed through preclinical and clinical trials and have been available - for years in some cases -before being recalled by the FDA for unanticipated toxicity in humans. One reason for such poor translation from drug candidate to successful use is a lack of model systems that accurately recapitulate normal tissue function of human organs and their response to drug compounds. Moreover, tissues in the body do not exist in isolation, but reside in a highly integrated and dynamically interactive environment, in which actions in one tissue can affect other downstream tissues. Few engineered model systems, including the growing variety of organoid and organ-on-a-chip platforms, have so far reflected the interactive nature of the human body. To address this challenge, we have developed an assortment of bioengineered tissue organoids and tissue constructs that are integrated in a closed circulatory perfusion system, facilitating inter-organ responses. We describe a three-tissue organ-on-a-chip system, comprised of liver, heart, and lung, and highlight examples of inter-organ responses to drug administration. We observe drug responses that depend on inter-tissue interaction, illustrating the value of multiple tissue integration for in vitro study of both the efficacy of and side effects associated with candidate drugs.